Please login to the form below

Not currently logged in
Email:
Password:

Andrew Witty appointed president of EFPIA

The European Federation of Pharmaceutical Industries and Associations has appointed Andrew Witty, CEO of GlaxoSmithKline, as its new president

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has appointed Andrew Witty, CEO of GlaxoSmithKline (GSK), as its new president. Witty will succeed outgoing president, Arthur Higgins, CEO of Bayer Healthcare.

 

Andrew Witty

 Andrew Witty
 


Commenting on his appointment, Witty said: "I am pleased to have the opportunity to represent our industry in Europe at this challenging time, when the policy considerations of healthcare have probably never been more pertinent. I thank Arthur Higgins for the focus he brought to the role of president, and the solid base it provides. As a result of his efforts, we are well prepared for future engagement and cooperation with the new Commission, European Parliament, Member States, patients and other stakeholders."

Witty, who has been vice-president of the EFPIA since 2008, went on to say: "Europe needs a 21st century approach to healthcare; one that provides access to optimal and equitable quality of care in a manner that is sustainable. We need policies that make this a reality, as well as policies that recognise innovation, equipping us to develop new medicines and therapies that citizens seek."

Higgins is also relinquishing his post at Bayer, for personal reasons. He is expected to be replaced by Marijn Dekkers, formerly of Thermo Fisher Scientific.

7th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics